NIVOLUMAB

Brand name:

• Opdivo®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Muscle invasive urothelial carcinoma (MIUC)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to listing (Matters arising/Matters outstanding)

Comment:

--

Submission sponsor:

Bristol-Myers Squibb Australia Pty Ltd

Other PBAC consideration:

• NIVOLUMAB
• NIVOLUMAB

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

10/04/2024

Lodgement of required documentation:

23/04/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 03/06/2024

Status:

Finalised

Government processes:

Commenced on 18/06/2024

Medicine listed on the PBS:

01/08/2024 (see PBS schedule)

---